Tamoxifen: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
(see also) |
|||
| Line 1: | Line 1: | ||
Tamoxifen | |||
| Line 11: | Line 11: | ||
== See also == | == See also == | ||
* [http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=24900307 Tamoxifen at PubChem] | |||
* [http://en.wikipedia.org/wiki/Tamoxifen Tamoxifen in the Wikipedia] | |||
* [http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=T5648|SIGMA&N5=SEARCH_CONCAT_PNO|BRAND_KEY&F=SPEC Tamoxifen] and [http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=T9262|SIGMA&N5=SEARCH_CONCAT_PNO|BRAND_KEY&F=SPEC Tamoxifen citrate datasheets] on the Sigma website | |||
* [http://en.wikipedia.org/wiki/Estrogen_receptor Estrogen receptor in the Wikipedia] | |||
Revision as of 01:58, 6 April 2009
Tamoxifen
Molecular mechanism of action
Tamoxifen competitively binds to GPCR type and intracellular type estrogen receptors (ER). Binding to the intracellular ER on tumours and other tissue targets produces a nuclear complex that decreases DNA synthesis and inhibits estrogen effects. It thus acts as an estrogen antagonists which inhibits the growth of some tumours dependent on estrogen stimulation.
Tamoxifen itself is a prodrug, having relatively little affinity for the estrogen receptor. It is metabolised in the liver by the cytochrome P450 to active metabolites such as 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen.
